Indigo is recognized alongside most ambitious and innovative companies representing breakthrough ideas from all over the world Boston, Massachusetts, May 22, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has been named to the sixth annual CNBC Disruptor 50 List, a ranked list of the most ambitious and innovative companies representing breakthrough ideas from all over the world. Indigo’s #18 ranking caps a remarka

-- Strategic focus on unleashing therapeutic potential of specific orphan GPCRs, including novel family of Mas-Related G-Protein Receptors (Mrgprs) -- Opportunity to pursue novel therapeutics for a broad range of indications; initial focus on neuro-immuno-inflammatory and autoreactive diseases -- Series A investors include The Column Group, 5AM Ventures and Osage University Partners -- Co-founders bring deep expertise in GPCR scientific research and drug development, and prov

Xconomy San Francisco — Unity Biotechnology has yet to show that its drugs can treat diseases of aging in humans, but it now has $85 million to start those tests. The Brisbane, CA, drug developer priced its initial public offering late Wednesday by selling 5 million shares at $17 apiece, the midpoint of the $16 to $18 range it had previously set. Shares are expected to begin trading Thursday on the Nasdaq exchange under the stock symbol “UBX.” Unity aims to treat diseases of